บรรณานุกรม

1. สังวาลย์ รักษ์เผ่า. ระเบียบวิธีวิจัยและสถิติในการวิจัยทางคลินิก. เชียงใหม่: คณะ
   แพทยศาสตร์ มหาวิทยาลัยเชียงใหม่; 2538:485-536.

2. อาภรณี ไชยาคำ. การติดตามตรวจวัดระดับยาในเลือด. ขอนแก่น: คณะเภสัชศาสตร์
   มหาวิทยาลัยขอนแก่น; 2543:135-59.

3. North JB, Penhall RK, Hanieh A, et al. Phenytoin and postoperative epilepsy: a double-
   blind study. J Neurosurg 1983;58:672–7.

4. Temkin NR, Kikmen SS, Wilensky AJ, et al. A randomized double-blind study of
   phenytoin for the prevention of post-traumatic seizures. N Engl J Med 1990;323
   (8):497-502.

5. Gerald ES. Therapeutic Drug Monitoring. East Norwalk: Appleton & Lange; 1995. 367-
   74.

6. Regional Laboratory for Toxicology. The TDM Guideline. [serial on the Internet]. 2002
   June 28 [cited 2004 Aug 25]; Available from: URL: http://www.toxlab.co.uk/tdm.htm

7. Wylie CR, Louis CB. Advanced Engineering Mathematics. 5th Ed. Tokyo: McGraw-
   Hill Book Company; 1985. 271.

8. Dowse R, Fulter WT. Outpatient compliance with theophylline and phenytoin therapy.
   S Afr Med J 1991;7:80 (11):550–3.

9. Cramer JA, Mattson RH, Prevay ML, et al. How often is medication taken as
   prescribed: A novel assessment technique. JAMA 1989;261():3273-7.

10. Desai BT. Active noncompliance as a cause af uncontrolled seizures. Epilepsia 1978;19
    (5):447–52.

11. Ludden TM. Sensitivity analysis of the effect of bioavailability or dosage form content
    on mean steady state phenytoin concentration. Ther Drug Monit 1991;13:120-5.

12. Giuseppe B. The bioequivalence and therapeutic efficacy of generic versus brand name
    psychoactive drug. Clin Ther 2003;25(6):1578-92.

13. Metzler CM. Computation problems of compartment models. Michaelis Menten–type
    elimination. J Pharm Sci 1981;70(7):733-7.

14. Shargel L. Applied Biopharmaceutics and Pharmacokinetics. 4th ed. New York: York Production Services; 1999; 449-74.

15. Lewis BS. Forcasting individual pharmacokinetics. Clin Pharmacol Ther 1979;26 (3):294-305.

16. Ratanakorn D, Kaojarern S, Phuapradit P. Single oral loading dose of phenytoin: a pharmacokinetic study. J Neuro Sci 1997;147:89-92.

17. Yukawa E. Clinical evaluation of population pharmacokinetic parameters in phenytoin dosage adjustment. Clin Pharm Bull 1989;37(12):3363-6.

18. Thomson AH. Bayesian parameter estimation and population pharmacokinetics. Clin Pharm 1992;22(6):447-67.

19. Armijo JA. Graphic estimation of phenytoin dose in adults and children. Ther Drug Monit 1991;13(6):507-10.

20. Randy DA. Updated comparison of drug dosing methods part I phenytoin. Clin Pharm 1991;20(3):209-17.

21. Ludden TM, Beal SL, et al. Evaluation of a Bayesian regression-analysis computer program for predicting phenytoin concentration. Clin Pharm 1986; Jul;5(7):580-5.

22. Killilea T. Bayesian regression analysis of non-steady state phenytoin concentration: evaluation of predictive performance. Ther Drug Monit 1989;11(4):455-62.

23. Choy M, Winter ME. Comparing mass-balance algorithm with a Bayesian regression analysis computer program for predicting serum phenytoin concentrations. Am J Health Syst Pharm 1998;15:2392-6.

24. Garcia MJ. Predictive performance of two phenytoin pharmacokinetic dosing programs from non steady state data. Ther Drug Monit 1994;16(4):380-7.

25. Toscano JP. Comparison of four single-point phenytoin dosage prediction techniques using computer simulated pharmacokinetic values. Clin Pharm 1986;5(5):396-402.

26. Scheyer RD. A method for prediction of phenytoin levels in the clinical setting. Comput Biomed Res 1991;24(6):564-75.

27. Desoky EE. Generation of pharmacokinetic data during routine therapeutic drug monitoring: Bayesian approach vs. pharmacokinetic studies. Ther Drug Monit 1993;15:281-8.

28. van der Weide J, Stijns LS, van Weelden MJ. The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement. Pharmacogenetics 2001; Jun; 11(4):287-91.